Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
The RV144 vaccine trial showed reduced risk of HIV-1 acquisition, but mechanisms underlying protection are poorly understood. Here, Fourati et al. assess the transcriptomic profile of blood collected from 223 vaccinees and 40 placebo recipients and identify IRF7 as a mediator of protection.
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-02-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-08854-2 |